Home › Funds › PRIMECAP MANAGEMENT CO/CA/ › GSK

PRIMECAP MANAGEMENT CO/CA/ position in GSK

GSK PLC · Health Care

PRIMECAP MANAGEMENT CO/CA/ reported holding 25,192,138 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$1.21B, representing 0.75% of its reported portfolio and ranking #35 among its reported holdings. PRIMECAP MANAGEMENT CO/CA/ has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)25.19M sh
Reported value held$1.21B
Portfolio Weight0.75%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How PRIMECAP MANAGEMENT CO/CA/'s GSK position evolved

PRIMECAP MANAGEMENT CO/CA/ first disclosed a stake in GSK in Q3 2023 at 12,058,770 shares (US$437.1M). The position peaked in Q1 2026 at 25,204,538 shares, worth US$1.39B. Across 13 filings, PRIMECAP MANAGEMENT CO/CA/ increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 25,192,138 shares valued at US$1.21B. Notable position changes include a 70% increase in Q4 2024 (shares rose 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 12.06M $437.13M New
Q4 2023 12.09M $448.03M Hold
Q1 2024 12.74M $546.09M Add
Q2 2024 14.51M $558.69M Add
Q3 2024 14.85M $607.22M Add
Q4 2024 25.26M $854.35M Add
Q1 2025 25.71M $995.93M Add
Q2 2025 27.73M $1.06B Add
Q3 2025 25.77M $1.11B Reduce
Q4 2025 25.13M $1.23B Reduce
Q1 2026 25.20M $1.39B Hold
Q2 2026 25.18M $1.32B Hold
Q3 2026 25.19M $1.21B Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), JTC Employer Solutions Trustee Ltd (US$389.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has PRIMECAP MANAGEMENT CO/CA/ held GSK?

PRIMECAP MANAGEMENT CO/CA/ has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is PRIMECAP MANAGEMENT CO/CA/'s current position in GSK?

As of Q3 2026, PRIMECAP MANAGEMENT CO/CA/ holds 25.19M shares of GSK (GSK PLC), valued at $1.21B, representing 0.75% of its reported portfolio and ranking #35.

Has PRIMECAP MANAGEMENT CO/CA/ been buying or selling GSK?

In the latest 13F filing (Q3 2026), PRIMECAP MANAGEMENT CO/CA/ held unchanged its position in GSK. The position peaked in Q1 2026 at 25.20M shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, JTC Employer Solutions Trustee Ltd, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.